Brokerages expect Aptinyx Inc (NASDAQ:APTX) to report $950,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aptinyx’s earnings. The lowest sales estimate is $890,000.00 and the highest is $1.00 million. Aptinyx reported sales of $940,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 1.1%. The business is expected to announce its next earnings report on Tuesday, November 12th.
On average, analysts expect that Aptinyx will report full year sales of $3.78 million for the current fiscal year, with estimates ranging from $3.56 million to $4.00 million. For the next year, analysts expect that the firm will report sales of $2.89 million, with estimates ranging from $1.78 million to $4.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Aptinyx.
Aptinyx (NASDAQ:APTX) last announced its earnings results on Monday, August 12th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.16. The business had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.95 million. Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%.
Large investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can purchased a new stake in Aptinyx in the 4th quarter worth $40,000. Metropolitan Life Insurance Co. NY increased its stake in Aptinyx by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock worth $120,000 after buying an additional 5,652 shares in the last quarter. Barclays PLC increased its stake in Aptinyx by 87.1% in the 4th quarter. Barclays PLC now owns 9,323 shares of the company’s stock worth $154,000 after buying an additional 4,340 shares in the last quarter. Gabelli Funds LLC purchased a new stake in Aptinyx in the 1st quarter worth $44,000. Finally, Bank of America Corp DE increased its stake in Aptinyx by 430.0% in the 4th quarter. Bank of America Corp DE now owns 13,213 shares of the company’s stock worth $218,000 after buying an additional 10,720 shares in the last quarter. Hedge funds and other institutional investors own 58.30% of the company’s stock.
APTX traded up $0.03 during mid-day trading on Wednesday, reaching $3.25. 134,733 shares of the company traded hands, compared to its average volume of 342,933. The firm has a market cap of $118.47 million, a PE ratio of -1.23 and a beta of -0.03. The stock’s fifty day moving average is $3.62. Aptinyx has a 52-week low of $2.88 and a 52-week high of $32.25.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Read More: What is Compound Annual Growth Rate (CAGR)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.